Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvaxovid Omicron Subvariant Vaccine in High-Risk Individuals
NCT07861542Phase 4Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 4 trial of SARS-CoV-2 rS antigen in coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Started Oct 2026; status: recruiting.
02
Drugs
SARS-CoV-2 rS antigen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07861542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861542.